You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology
On demand events

EADV 2023 Symposium: New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

Review the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies.

Stephan Weidinger
Lawrence F. Eichenfield
Marlies de Graaf
MD, PhD
Stephan Weidinger +2 more

On demand materials

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management
Dermatology
expert video

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children
Dermatology
expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

Current Treatment Landscape and Emerging Therapies
Dermatology
expert video

Current Treatment Landscape and Emerging Therapies

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health
Dermatology
expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD
Dermatology
expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

How Can We Explore the Concept of Disease Modification in Children With AD?
Dermatology
expert video

How Can We Explore the Concept of Disease Modification in Children With AD?

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Dermatology
Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Learning objectives

  • Describe the cumulative impact of the burdens of atopic dermatitis in children, and the potential consequences later in life
  • Explore the potential of early control of type 2 inflammation to modify disease course
  • Review the evolving therapeutic landscape for children with atopic dermatitis, considering clinically relevant data supporting the use of advanced systemic therapies

Description

Watch the ADVENT symposium ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presented at EADV 2023, where Drs. Weidinger, de Graaf and Eichenfield present the latest advances on managing patients with atopic dermatitis.

Tags
symptomsbiologicsjak inhibitorssymposium
MAT-GLB-2305477 V2 11/2023

About these experts

Dermatology
MD, PhD

Stephan Weidinger

Professor and Chair for Dermatology at the Christian-Albrechts-University; Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, Campus Kiel, Germany

Dermatology
MD

Lawrence F. Eichenfield

Vice Chair of the Department of Dermatology | University of California San Diego (UCSD) School of Medicine; Chief of Pediatric and Adolescent Dermatology | Rady Children’s Hospital San Diego, California, United States

Dermatology
MD, PhD

Marlies de Graaf

Pediatric Dermatologist, University Medical Center of Utrecht, The Netherlands

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region